New trial finds arthritis drug no better than standard care for severe COVID-19

Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, according to results of a new trial.

Source: ScienceDaily.com